Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

4613 - The efficacy and safety of crizotinib in patients with ROS1 positive advanced stage NSCLC: The real-world experience from Turkey


20 Oct 2018


Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research


Targeted Therapy

Tumour Site


Saadettin Kilickap


Annals of Oncology (2018) 29 (suppl_8): viii493-viii547. 10.1093/annonc/mdy292


S. Kilickap1, Ö.F. Ölmez2, I. Cicin3, U. Demirci4, O. Alan5, D. Cabuk6, T. Şakalar7, A.M. Tatlı8, F. Başol Buğdaycı9, Y. Eralp10, M. Uysal11, A. Demirkazık12, B. Bilgin13, B. Yıldız14, M. Karaağaç15, K. Okutur16, A. Sakin17

Author affiliations

  • 1 Medical Oncology, Hacettepe University Faculty of Medicine, 6100 - Ankara/TR
  • 2 Department Of Medical Oncology, Medipol University, Istanbul/TR
  • 3 Department Of Medical Oncology, Trakya University Faculty of Medicine, Edirne/TR
  • 4 Department Of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Onkoloji Training and Research Hospital, 6200 - Ankara/TR
  • 5 Medical Oncology, Marmara University Hospital, 34600 - Istanbul/TR
  • 6 Department Of Medical Oncology, Kocaeli University, 41380 - Kocaeli/TR
  • 7 Medical Oncology, Erciyer University School of Medicine, 80350 - Kayseri/TR
  • 8 Department Of Medical Oncology, Akdeniz University Faculty of Medicine, Antalya/TR
  • 9 Department Of Medical Oncology, Sanatoryum Chest Disease Hospital, Ankara/TR
  • 10 Department Of Medical Oncology, Istanbul University Faculty of Medicine, İstanbul/TR
  • 11 Department Of Medical Oncology, Afyon Kocatepe University Faculty of Medicine, Afyon/TR
  • 12 Department Of Medical Oncology, Ankara University faculty of Medicine, Ankara/TR
  • 13 Department Of Medical Oncology, Yildirim Beyazit University Faculty of Medicine, Ankara/TR
  • 14 Department Of Medical Oncology, Gulhane Education and Research Hospital, Ankara/TR
  • 15 Department Of Medical Oncology, Meram University Faculty of Medicine, Konya/TR
  • 16 Department Of Medical Oncology, MedicalPark Hospitals, İstanbul/TR
  • 17 Department Of Medical Oncology, Okmeydanı Education and Research Hospital, Istanbul/TR


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4613


ROS1 mutation occurs in approximately 1-2% of patients with NSCLC. There are limited data on the efficacy of crizotinib therapy in the treatment of ROS1-positive advanced stage NSCLC. The survival results of two studies evaluating the efficacy of crizotinib in these patients are contradictory. In the study, we aimed to evaluate real life data of the patients with ROS1 positive advanced stage NSCLC treated with crizotinib in Turkey.


In this multicenter study, patients with ROS1-positive NSCLC treated with crizotinib were retrospectively analyzed. Clinical and demographic characteristics of the disease, response rates median PFS and side effects with crizotinib were evaluated in 42 patients.


Twenty-two of the patients (52.4%) were female, and 23 (54.8%) were non-smoker. The median age at the time of diagnosis was 51 (20-80) years. The most common histology was adenocarcinoma (n ve %). At baseline, 12 (28.6%) patients had pleural effusion, 11 (26.2%) had brain metastasis, and 17 (40.5%) had bone metastasis. The baseline ECOG performance score was "0" in 28.6% and “1” in 64.3%. Crizotinib was used in 45.2% of patients at the first line, 42.9% at the second line, and 12.0% in the next steps. The most common side effect was fatigue (43%). In 4 patients vascular event developed (3 thromboemboli, 1 acute MI). Brain metastasis developed in 31% of the patients at the follow-up. The overall response rate with crizotinib was 59.5% with 9.5% complete remission and 50.0% partial remission. The disease control rate was 83.3%. The median PFS was 13.2 months and the 12-month PFS was 53%. Twelve-month OS was 62%, the median OS was 25 months. Two patients who developed progression were treated with lorlatinib and one patient was treated with ceritinib and and then alectinib. Overall survival in these patients were 24 months, 28 months and 13.7 months, respectively.


In 2 published studies, median PFS in patients with ROS1-positive NSCLC with treated crizotinib were reported as 9.1 and 19.2 months independently of the treatment step. In our study, the median PFS was 13.2 months in patients as a result of real-life data of patients in Turkey. The clinical features of the disease are compatible with the literature.

Clinical trial identification

Legal entity responsible for the study

Turkish Oncology Group, Lung Cancer Subgrup.


Has not received any funding.

Editorial Acknowledgement


S. Kilickap: Pfizer. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.